MEOBF
Mesoblast Limited
Price Chart
Latest Quote
$1.55
+0.00 (+0.00%)
Current Price
| Previous Close | $1.55 |
| Open | $1.70 |
| Day High | $1.70 |
| Day Low | $1.70 |
| Volume | 5,000 |
Stock Information
| Shares Outstanding | 1.29B |
| Total Debt | $135.14M |
| Cash Equivalents | $129.97M |
| Revenue | $65.38M |
| Net Income | $-94.37M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.00B |
| EPS (TTM) | $-0.07 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.00B |
| Sales | $65.38M |
| Income | $-94.37M |
| Book/sh | $0.45 |
| Cash/sh | $0.10 |
| Employees | 81 |
Financial Ratios
| Quick Ratio | 1.35 |
| Current Ratio | 1.58 |
| Debt/Eq | 23.52 |
Returns & Margins
| ROA | -6.16% |
| ROE | -18.22% |
| Gross Margin | -35.53% |
| Operating Margin | -55.16% |
| Profit Margin | -144.33% |
Ownership
| Insider Ownership | 36.25% |
| Institutional Ownership | 16.69% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| PEG | 0.14 |
| P/S | 30.65 |
| P/B | 3.48 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $1.61 |
| SMA50 | $1.66 |
| SMA200 | $1.60 |
| ATR | 0.0107 |
| Shares Float | 833.84M |
| Volatility | 0.79 |
Performance History
| Week | +0.00% |
| Month | -8.82% |
| Quarter | +0.00% |
| 6 Months | +14.81% |
| YTD | -18.42% |
| Year | +59.79% |
| 3 Years | +72.22% |
| 5 Years | -4.91% |
| 10 Years | +121.43% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $1.55 | 0 |
| 2026-06-23 | $1.55 | 0 |
| 2026-06-22 | $1.55 | 0 |
| 2026-06-18 | $1.55 | 0 |
| 2026-06-17 | $1.55 | 0 |
| 2026-06-16 | $1.55 | 0 |
| 2026-06-15 | $1.55 | 0 |
| 2026-06-12 | $1.55 | 0 |
| 2026-06-11 | $1.55 | 0 |
| 2026-06-10 | $1.55 | 0 |
| 2026-06-09 | $1.55 | 0 |
| 2026-06-08 | $1.55 | 2,000 |
| 2026-06-05 | $1.70 | 0 |
| 2026-06-04 | $1.70 | 0 |
| 2026-06-03 | $1.70 | 0 |
| 2026-06-02 | $1.70 | 0 |
| 2026-06-01 | $1.70 | 0 |
| 2026-05-29 | $1.70 | 0 |
| 2026-05-28 | $1.70 | 0 |
| 2026-05-27 | $1.70 | 0 |
| 2026-05-26 | $1.70 | 0 |
About Mesoblast Limited
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and GrÃŧnenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
đ° Latest News
Kina Securities And 2 Other Stocks That May Be Trading Below Their Estimated Value On The ASX
Simply Wall St. âĸ 2026-06-11T19:35:02Z
ASX Growth Companies With High Insider Ownership
Simply Wall St. âĸ 2026-05-31T19:38:09Z
ASX Penny Stocks With Market Caps Under A$3B To Consider
Simply Wall St. âĸ 2026-05-28T03:05:21Z
ASX Stocks Trading At An Estimated Discount Of Up To 45.8% Below Intrinsic Value
Simply Wall St. âĸ 2026-05-13T19:34:42Z
How Completion Of RMAT Phase 3 Enrollment At Mesoblast (ASX:MSB) Has Changed Its Investment Story
Simply Wall St. âĸ 2026-05-01T22:19:34Z
ASX Penny Stocks To Watch In April 2026
Simply Wall St. âĸ 2026-04-29T20:02:44Z
ASX Growth Companies With High Insider Ownership In April 2026
Simply Wall St. âĸ 2026-04-29T19:38:20Z
Assessing Mesoblastâs Valuation After Recent Share Price Weakness And Conflicting Growth Signals
Simply Wall St. âĸ 2026-04-29T02:08:10Z
Mesoblast Ltd (MESO): Secure Exclusive Rights to a Vital Platform
Insider Monkey âĸ 2026-04-28T17:30:05Z
Why Mesoblast Limited (MESO) is One of the Best Low Priced Biotech Stocks to Invest in
Insider Monkey âĸ 2026-04-20T00:11:34Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $5,130,000 | $0 | $0 | - |
| Cost Of Revenue | $5,130,000 | $0 | $0 | - |
| Total Revenue | $17,198,000 | $5,902,000 | $7,501,000 | $10,211,000 |
| Operating Revenue | $17,198,000 | $5,902,000 | $7,501,000 | $10,211,000 |
| Expenses | ||||
| Interest Expense | $21,753,000 | $20,658,000 | $19,444,000 | $17,288,000 |
| Total Expenses | $79,641,000 | $63,874,000 | $76,790,000 | $91,318,000 |
| Other Income Expense | $-20,371,000 | $-11,341,000 | $5,801,000 | $6,809,000 |
| Net Non Operating Interest Income Expense | $-18,998,000 | $-18,834,000 | $-18,613,000 | $-17,288,000 |
| Total Other Finance Cost | $799,000 | - | $678,000 | $382,000 |
| Interest Expense Non Operating | $21,753,000 | $20,658,000 | $19,444,000 | $17,288,000 |
| Operating Expense | $74,511,000 | $63,874,000 | $76,790,000 | $91,318,000 |
| Other Operating Expenses | $-85,000 | $-859,000 | $-3,506,000 | $536,000 |
| Selling And Marketing Expense | $16,102,000 | $11,789,000 | $13,940,000 | $30,757,000 |
| General And Administrative Expense | $23,207,000 | $13,191,000 | $13,540,000 | $27,210,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-102,142,000 | $-87,956,000 | $-81,889,000 | $-91,347,000 |
| Net Interest Income | $-18,998,000 | $-18,834,000 | $-18,613,000 | $-17,288,000 |
| Interest Income | $3,554,000 | $1,824,000 | $831,000 | $3,000 |
| Normalized Income | $-87,882,300 | $-76,639,574 | $-87,675,021 | $-98,138,231 |
| Net Income From Continuing And Discontinued Operation | $-102,142,000 | $-87,956,000 | $-81,889,000 | $-91,347,000 |
| Net Income Common Stockholders | $-102,142,000 | $-87,956,000 | $-81,889,000 | $-91,347,000 |
| Net Income | $-102,142,000 | $-87,956,000 | $-81,889,000 | $-91,347,000 |
| Net Income Including Noncontrolling Interests | $-102,142,000 | $-87,956,000 | $-81,889,000 | $-91,347,000 |
| Net Income Continuous Operations | $-102,142,000 | $-87,956,000 | $-81,889,000 | $-91,347,000 |
| Pretax Income | $-101,812,000 | $-88,147,000 | $-82,101,000 | $-91,586,000 |
| Special Income Charges | $-15,303,000 | $-12,044,000 | $8,169,000 | $913,000 |
| Interest Income Non Operating | $3,554,000 | $1,824,000 | $831,000 | $3,000 |
| Operating Income | $-62,443,000 | $-57,972,000 | $-69,289,000 | $-81,107,000 |
| Gross Profit | $12,068,000 | $5,902,000 | $7,501,000 | - |
| Per Share | ||||
| Diluted EPS | $-0.08 | $-0.09 | $-0.11 | $-13.38 |
| Basic EPS | $-0.08 | $-0.09 | $-0.11 | $-13.38 |
| Other | ||||
| Tax Effect Of Unusual Items | $-6,111,300 | $-24,574 | $14,979 | $17,769 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-59,688,000 | $-56,148,000 | $-68,458,000 | $-81,107,000 |
| Total Unusual Items | $-20,371,000 | $-11,341,000 | $5,801,000 | $6,809,000 |
| Total Unusual Items Excluding Goodwill | $-20,371,000 | $-11,341,000 | $5,801,000 | $6,809,000 |
| Reconciled Depreciation | $6,400,000 | $4,666,000 | $4,107,000 | $4,380,000 |
| EBITDA (Bullshit earnings) | $-80,059,000 | $-67,489,000 | $-62,657,000 | $-74,298,000 |
| EBIT | $-80,059,000 | $-67,489,000 | $-62,657,000 | $-74,298,000 |
| Diluted Average Shares | $1,207,793,132 | $986,702,919 | $777,719,091 | $682,861,425 |
| Basic Average Shares | $1,207,793,132 | $986,702,919 | $777,719,091 | $682,861,425 |
| Diluted NI Availto Com Stockholders | $-102,142,000 | $-87,956,000 | $-81,889,000 | $-91,347,000 |
| Tax Provision | $330,000 | $-191,000 | $-212,000 | $-239,000 |
| Gain On Sale Of Ppe | $0 | $0 | $76,000 | $0 |
| Other Special Charges | $416,000 | $2,351,000 | $678,000 | $382,000 |
| Restructuring And Mergern Acquisition | $14,887,000 | $9,693,000 | $-8,771,000 | $-913,000 |
| Gain On Sale Of Security | $-5,068,000 | $703,000 | $-2,368,000 | $5,896,000 |
| Other Taxes | $480,000 | $37,000 | $0 | $3,000 |
| Research And Development | $34,807,000 | $39,716,000 | $52,816,000 | $32,815,000 |
| Selling General And Administration | $39,309,000 | $24,980,000 | $27,480,000 | $57,967,000 |
| Other Gand A | $4,473,000 | $2,438,000 | $3,019,000 | $27,210,000 |
| Salaries And Wages | $18,734,000 | $10,753,000 | $10,521,000 | $9,747,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $25,616,000 | $-95,381,000 | $-75,345,000 | $-81,608,000 |
| Total Assets | $784,683,000 | $669,153,000 | $669,415,000 | $662,142,000 |
| Total Non Current Assets | $580,333,000 | $582,690,000 | $587,757,000 | $592,305,000 |
| Other Non Current Assets | $475,000 | $481,000 | $481,000 | $500,000 |
| Non Current Prepaid Assets | $252,000 | $252,000 | $252,000 | $252,000 |
| Non Current Note Receivables | $569,000 | $1,179,000 | $1,179,000 | $1,178,000 |
| Investmentin Financial Assets | $1,388,000 | $1,014,000 | $1,757,000 | $1,758,000 |
| Goodwill And Other Intangible Assets | $571,826,000 | $575,736,000 | $577,183,000 | $578,652,000 |
| Other Intangible Assets | $437,373,000 | $441,283,000 | $442,730,000 | $444,199,000 |
| Current Assets | $204,350,000 | $86,463,000 | $81,658,000 | $69,837,000 |
| Restricted Cash | $393,000 | $397,000 | $398,000 | $413,000 |
| Prepaid Assets | $5,687,000 | $2,551,000 | $3,342,000 | $4,987,000 |
| Inventory | $22,246,000 | $0 | - | - |
| Receivables | $14,866,000 | $20,952,000 | $6,998,000 | $4,403,000 |
| Other Receivables | $188,000 | $17,778,000 | $195,000 | - |
| Taxes Receivable | $765,000 | $1,748,000 | $4,509,000 | $2,179,000 |
| Accrued Interest Receivable | $2,000 | $23,000 | $18,000 | $0 |
| Accounts Receivable | $13,911,000 | $1,403,000 | $2,276,000 | $2,224,000 |
| Cash Cash Equivalents And Short Term Investments | $161,158,000 | $62,563,000 | $70,920,000 | $60,034,000 |
| Cash And Cash Equivalents | $161,158,000 | $62,563,000 | $70,920,000 | $60,034,000 |
| Cash Financial | $161,158,000 | $62,563,000 | $70,920,000 | $60,034,000 |
| Non Current Accounts Receivable | - | $190,000 | $414,000 | - |
| Cash Equivalents | - | - | - | - |
| Debt | ||||
| Total Debt | $128,157,000 | $118,923,000 | $116,495,000 | $106,905,000 |
| Long Term Debt And Capital Lease Obligation | $71,322,000 | $102,435,000 | $106,483,000 | $98,702,000 |
| Long Term Debt | $67,739,000 | $100,483,000 | $102,811,000 | $91,617,000 |
| Current Debt And Capital Lease Obligation | $56,835,000 | $16,488,000 | $10,012,000 | $8,203,000 |
| Current Debt | $54,155,000 | $13,862,000 | $5,952,000 | $5,017,000 |
| Other Current Borrowings | $54,155,000 | $13,862,000 | $5,952,000 | $5,017,000 |
| Net Debt | - | $51,782,000 | $37,843,000 | $36,600,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $187,241,000 | $188,798,000 | $167,577,000 | $165,098,000 |
| Total Non Current Liabilities Net Minority Interest | $84,615,000 | $115,555,000 | $125,595,000 | $113,725,000 |
| Other Non Current Liabilities | $10,778,000 | $10,594,000 | - | - |
| Non Current Deferred Liabilities | $2,500,000 | $2,500,000 | $2,500,000 | $2,500,000 |
| Current Liabilities | $102,626,000 | $73,243,000 | $41,982,000 | $51,373,000 |
| Other Current Liabilities | $16,725,000 | $20,945,000 | $5,426,000 | $2,185,000 |
| Payables And Accrued Expenses | $19,082,000 | $7,070,000 | $20,145,000 | $23,079,000 |
| Payables | $19,082,000 | $7,070,000 | $20,145,000 | $23,079,000 |
| Accounts Payable | $19,082,000 | $7,070,000 | $20,145,000 | $23,079,000 |
| Non Current Deferred Taxes Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $597,442,000 | $480,355,000 | $501,838,000 | $497,044,000 |
| Total Equity Gross Minority Interest | $597,442,000 | $480,355,000 | $501,838,000 | $497,044,000 |
| Stockholders Equity | $597,442,000 | $480,355,000 | $501,838,000 | $497,044,000 |
| Gains Losses Not Affecting Retained Earnings | $99,499,000 | $78,303,000 | $73,520,000 | $70,651,000 |
| Retained Earnings | $-1,010,903,000 | $-908,761,000 | $-820,805,000 | $-738,916,000 |
| Other | ||||
| Treasury Shares Number | $32,389 | $542,903 | $572,593 | $572,593 |
| Ordinary Shares Number | $1,279,934,798 | $1,141,241,211 | $858,159,058 | $685,453,691 |
| Share Issued | $1,279,967,187 | $1,141,784,114 | $858,731,651 | $686,026,284 |
| Tangible Book Value | $25,616,000 | $-95,381,000 | $-75,345,000 | $-81,608,000 |
| Invested Capital | $719,336,000 | $594,700,000 | $610,601,000 | $593,678,000 |
| Working Capital | $101,724,000 | $13,220,000 | $39,676,000 | $18,464,000 |
| Capital Lease Obligations | $6,263,000 | $4,578,000 | $7,732,000 | $10,271,000 |
| Total Capitalization | $665,181,000 | $580,838,000 | $604,649,000 | $588,661,000 |
| Capital Stock | $1,508,846,000 | $1,310,813,000 | $1,249,123,000 | $1,165,309,000 |
| Common Stock | $1,508,846,000 | $1,310,813,000 | $1,249,123,000 | $1,165,309,000 |
| Employee Benefits | $15,000 | $26,000 | - | - |
| Long Term Capital Lease Obligation | $3,583,000 | $1,952,000 | $3,672,000 | $7,085,000 |
| Current Capital Lease Obligation | $2,680,000 | $2,626,000 | $4,060,000 | $3,186,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $6,234,000 | $7,436,000 | - | - |
| Current Provisions | $3,750,000 | $21,304,000 | $6,399,000 | $17,906,000 |
| Investments And Advances | $1,388,000 | $1,014,000 | $1,757,000 | $1,758,000 |
| Available For Sale Securities | $1,388,000 | $1,014,000 | $1,757,000 | $1,758,000 |
| Goodwill | $134,453,000 | $134,453,000 | $134,453,000 | $134,453,000 |
| Net PPE | $5,823,000 | $3,838,000 | $6,491,000 | $9,965,000 |
| Accumulated Depreciation | $-18,170,000 | $-20,290,000 | $-21,981,000 | $-18,320,000 |
| Gross PPE | $23,993,000 | $24,128,000 | $28,472,000 | $28,285,000 |
| Other Properties | $7,207,000 | $6,245,000 | $6,178,000 | $6,178,000 |
| Machinery Furniture Equipment | $9,648,000 | $8,755,000 | $12,337,000 | $12,150,000 |
| Buildings And Improvements | $7,138,000 | $9,128,000 | $9,957,000 | $9,957,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $21,183,000 | $0 | - | - |
| Work In Process | $0 | $0 | - | - |
| Raw Materials | $1,063,000 | $0 | - | - |
| Long Term Provisions | - | $10,620,000 | $16,612,000 | $12,523,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-50,684,000 | $-48,789,000 | $-63,583,000 | $-66,014,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-49,954,000 | $-48,458,000 | $-63,269,000 | $-65,782,000 |
| Cash Flow From Continuing Operating Activities | $-49,954,000 | $-48,458,000 | $-63,269,000 | $-65,782,000 |
| Operating Gains Losses | $4,985,000 | $-701,000 | $2,191,000 | $-5,360,000 |
| Cash Flowsfromusedin Operating Activities Direct | $-49,954,000 | $-48,458,000 | $-63,269,000 | $-65,782,000 |
| Classesof Cash Receiptsfrom Operating Activities | $6,609,000 | $10,599,000 | $8,618,000 | $10,004,000 |
| Other Cash Receiptsfrom Operating Activities | $905,000 | $3,819,000 | $1,118,000 | $24,000 |
| Investing Activities | ||||
| Capital Expenditure | $-730,000 | $-331,000 | $-314,000 | $-232,000 |
| Investing Cash Flow | $120,000 | $-97,000 | $-194,000 | $-232,000 |
| Cash Flow From Continuing Investing Activities | $120,000 | $-97,000 | $-194,000 | $-232,000 |
| Net Other Investing Changes | $609,000 | - | $120,000 | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $161,205,000 | $65,406,000 | $88,635,000 | $209,000 |
| Financing Cash Flow | $147,336,000 | $40,252,000 | $74,502,000 | $-9,870,000 |
| Cash Flow From Continuing Financing Activities | $147,336,000 | $40,252,000 | $74,502,000 | $-9,870,000 |
| Net Other Financing Charges | $-5,662,000 | $-5,915,000 | $-5,463,000 | $-5,749,000 |
| Cash Dividends Paid | $0 | $0 | $0 | $0 |
| Net Common Stock Issuance | $161,205,000 | $65,406,000 | $88,635,000 | $209,000 |
| Common Stock Issuance | $161,205,000 | $65,406,000 | $88,635,000 | $209,000 |
| Other | ||||
| Repayment Of Debt | $-9,765,000 | $-13,522,000 | $-2,656,000 | $-58,246,000 |
| End Cash Position | $161,551,000 | $62,960,000 | $71,318,000 | $60,447,000 |
| Beginning Cash Position | $62,960,000 | $71,318,000 | $60,447,000 | $136,881,000 |
| Effect Of Exchange Rate Changes | $1,089,000 | $-55,000 | $-168,000 | $-550,000 |
| Changes In Cash | $97,502,000 | $-8,303,000 | $11,039,000 | $-75,884,000 |
| Interest Paid Cff | $-5,266,000 | $-5,717,000 | $-6,014,000 | $-6,084,000 |
| Proceeds From Stock Option Exercised | $6,824,000 | $0 | $0 | $8,081,000 |
| Net Issuance Payments Of Debt | $-9,765,000 | $-13,522,000 | $-2,656,000 | $-6,327,000 |
| Net Long Term Debt Issuance | $-9,765,000 | $-13,522,000 | $-2,656,000 | $-6,327,000 |
| Long Term Debt Payments | $-9,765,000 | $-13,522,000 | $-2,656,000 | $-58,246,000 |
| Net Investment Purchase And Sale | $241,000 | $234,000 | $120,000 | $0 |
| Sale Of Investment | $241,000 | $234,000 | $120,000 | $0 |
| Net Intangibles Purchase And Sale | $-50,000 | $-60,000 | $-50,000 | $-75,000 |
| Purchase Of Intangibles | $-50,000 | $-60,000 | $-50,000 | $-75,000 |
| Net PPE Purchase And Sale | $-680,000 | $-271,000 | $-264,000 | $-157,000 |
| Purchase Of PPE | $-680,000 | $-271,000 | $-264,000 | $-157,000 |
| Change In Working Capital | $-3,042,000 | $-2,631,000 | $-2,472,000 | $4,869,000 |
| Change In Other Working Capital | $-18,919,000 | $22,916,000 | $-1,218,000 | $-1,603,000 |
| Change In Payables And Accrued Expense | $11,780,000 | $-12,378,000 | $-398,000 | $4,777,000 |
| Change In Payable | $11,780,000 | $-12,378,000 | $-398,000 | $4,777,000 |
| Change In Prepaid Assets | $-3,018,000 | $807,000 | $1,650,000 | $1,555,000 |
| Change In Inventory | $826,000 | $0 | $0 | - |
| Change In Receivables | $6,289,000 | $-13,976,000 | $-2,506,000 | $140,000 |
| Changes In Account Receivables | $5,021,000 | $-15,466,000 | $-118,000 | $140,000 |
| Other Non Cash Items | $21,427,000 | $32,485,000 | $11,351,000 | $16,375,000 |
| Stock Based Compensation | $22,088,000 | $5,870,000 | $3,655,000 | $5,536,000 |
| Deferred Tax | $330,000 | $-191,000 | $-212,000 | $-235,000 |
| Deferred Income Tax | $330,000 | $-191,000 | $-212,000 | $-235,000 |
| Depreciation Amortization Depletion | $6,400,000 | $4,666,000 | $4,107,000 | $4,380,000 |
| Depreciation And Amortization | $6,400,000 | $4,666,000 | $4,107,000 | $4,380,000 |
| Gain Loss On Investment Securities | $4,962,000 | $-779,000 | $2,205,000 | $-5,896,000 |
| Net Foreign Currency Exchange Gain Loss | $23,000 | $78,000 | $62,000 | $536,000 |
| Gain Loss On Sale Of PPE | $0 | $0 | $-76,000 | $0 |
| Net Income From Continuing Operations | $-102,142,000 | $-87,956,000 | $-81,889,000 | $-91,347,000 |
| Taxes Refund Paid Direct | $-2,000 | $4,000 | $20,000 | $-24,000 |
| Interest Received Direct | $3,549,000 | $1,778,000 | $796,000 | $7,000 |
| Classesof Cash Payments | $-60,112,000 | $-60,835,000 | $-72,683,000 | $-75,793,000 |
| Paymentsto Suppliersfor Goodsand Services | $-60,110,000 | $-60,835,000 | $-72,683,000 | $-75,769,000 |
| Receiptsfrom Customers | $5,704,000 | $6,776,000 | $7,480,000 | $9,980,000 |
| Issuance Of Debt | - | $0 | $0 | $51,919,000 |
| Long Term Debt Issuance | - | $0 | $0 | $51,919,000 |
| Net Business Purchase And Sale | - | - | - | $0 |
| Purchase Of Business | - | - | - | $0 |
| Change In Other Current Assets | - | - | - | - |
Fetched: 2026-02-02